Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 16% Improvement Relative Risk Pasquini et al. HCQ for COVID-19 ICU PATIENTS Is very late treatment with HCQ beneficial for COVID-19? Retrospective 51 patients in Italy Lower mortality with HCQ (not stat. sig., p=0.34) Pasquini et al., J. Antimicrobial Chemotherapy, doi:10.1093/jac/dkaa321 Favors HCQ Favors control
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU
Pasquini et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkaa321
Pasquini et al., Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkaa321
Aug 2020   Source   PDF  
  All Studies   Meta
Retrospective 51 ICU patients under mechanical ventilation, 33 treated with HCQ, showing unadjusted lower mortality with treatment.
Although the 16% lower mortality is not statistically significant, it is consistent with the significant 22% lower mortality [18‑27%] from meta analysis of the 232 mortality results to date. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 16.4% lower, RR 0.84, p = 0.34, treatment 23 of 33 (69.7%), control 15 of 18 (83.3%), NNT 7.3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pasquini et al., 23 Aug 2020, retrospective, Italy, peer-reviewed, 9 authors, average treatment delay 10.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: J Antimicrob Chemother 2020; 75: 3359–3365 doi:10.1093/jac/dkaa321 Advance Access publication 23 August 2020 Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU Zeno Pasquini1,2, Roberto Montalti3, Chiara Temperoni1, Benedetta Canovari1, Mauro Mancini4, Michele Tempesta5, Daniela Pimpini5, Nicoletta Zallocco4 and Francesco Barchiesi1,2* 1 *Corresponding author. E-mail: Received 20 May 2020; accepted 24 June 2020 Background: Remdesivir is a prodrug with in vitro activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Its clinical efficacy in patients with COVID-19 under mechanical ventilation remains to be evaluated. Methods: This study includes patients under mechanical ventilation with confirmed SARS-CoV-2 infection admitted to the ICU of Pesaro hospital between 29 February and 20 March 2020. During this period, remdesivir was provided on a compassionate use basis. Clinical characteristics and outcome of patients treated with remdesivir were collected retrospectively and compared with those of patients hospitalized in the same time period. Results: A total of 51 patients were considered, of which 25 were treated with remdesivir. The median (IQR) age was 67 (59–75.5) years, 92% were men and symptom onset was 10 (8–12) days before admission to ICU. At baseline, there was no significant difference in demographic characteristics, comorbidities and laboratory values between patients treated and not treated with remdesivir. Median follow-up was 52 (46–57) days. Kaplan–Meier curves showed significantly lower mortality among patients who had been treated with remdesivir (56% versus 92%, P < 0.001). Cox regression analysis showed that the Charlson Comorbidity Index was the only factor that had a significant association with higher mortality (OR 1.184; 95% CI 1.027–1.365; P = 0.020), while the use of remdesivir was associated with better survival (OR 3.506; 95% CI 1.768–6.954; P < 0.001). Conclusions: In this study the mortality rate of patients with COVID-19 under mechanical ventilation is confirmed to be high. The use of remdesivir was associated with a significant beneficial effect on survival.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop